Home Cart Sign in  
Chemical Structure| 112-86-7 Chemical Structure| 112-86-7

Structure of Erucic Acid
CAS No.: 112-86-7

Chemical Structure| 112-86-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Erucic acid is a monounsaturated omega-9 fatty acid used as mineral oil and a precursor to biodiesel fuel.

Synonyms: Docosenoic acid (cis-13); cis-13-docosenoic acid; C22:1(cis-13)Fatty acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Erucic Acid

CAS No. :112-86-7
Formula : C22H42O2
M.W : 338.57
SMILES Code : CCCCCCCC/C=C\CCCCCCCCCCCC(O)=O
Synonyms :
Docosenoic acid (cis-13); cis-13-docosenoic acid; C22:1(cis-13)Fatty acid
MDL No. :MFCD00063188
InChI Key :DPUOLQHDNGRHBS-KTKRTIGZSA-N
Pubchem ID :5281116

Safety of Erucic Acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Erucic Acid

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CD8+T cells 0.5 mM 24 hours Inhibited the effector function of CD8+T cells, reducing the production of inflammatory cytokines IFN-γ and TNF-α MedComm (2020). 2023 Sep 26;4(5):e382
A549 cells 0.3-0.9 μM 24 hours Erucic acid exerted inhibitory effects on IAV or viral (v) RNA-induced pro-inflammatory mediators as well as interferons (IFNs) through inactivation of NF-κB and p38 MAPK signaling. J Pharm Anal. 2020 Apr;10(2):130-146
MDCK cells 0.49-1.24 μM 48 hours Erucic acid exhibited broad-spectrum antiviral activity against IAV resulting from reduction of viral polymerase transcription activity. J Pharm Anal. 2020 Apr;10(2):130-146
Fibroblasts 250 µM 1 day Erucic acid effectively suppresses inflammation and upregulates osteogenic activators in fibroblasts exposed to fine dust. Additionally, erucic acid-induced exosomes (EIEs) strongly counteract the negative effects of fine dust on osteocytic differentiation and inflammation. J Funct Biomater. 2024 Jul 31;15(8):215

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Mouse-adapted A/FM/1/47-MA(H1N1) strain infection model Intragastric administration 50 or 100 mg/kg/day Once daily for 7 days Erucic acid administration consistently displayed decreased lung viral load and viral antigens expression, markedly reduced CD8+ cytotoxic T lymphocyte (CTL) recruitment, pro-apoptotic signaling, hyperactivity of multiple signaling pathways, and exacerbated immune inflammation in the lung, which resulted in decreased lung injury and mortality in mice. J Pharm Anal. 2020 Apr;10(2):130-146
MRL/lpr mice Systemic lupus erythematosus model Oral gavage 75 mg/kg Administered on gestational days 0.5, 5.5, 10.5, and 15.5 Improved placental damage and inhibited the effector function of uterine CD8+T cells MedComm (2020). 2023 Sep 26;4(5):e382

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.95mL

0.59mL

0.30mL

14.77mL

2.95mL

1.48mL

29.54mL

5.91mL

2.95mL

References

 

Historical Records

Categories